Cancers often exhibit high levels of cyclin E expression, and aberrant cyclin E activity causes genomic instability and increased tumorigenesis. Two tumor suppressor pathways protect cells against cyclin E deregulation. The p53 pathway is induced by excess cyclin E in primary cells and opposes cyclin E activity through induction of p21Cip1. In contrast, the Fbw7 pathway targets cyclin E for degradation, and Fbw7 mutations occur commonly in cancers. We investigated the cooperativity of these two pathways in countering cyclin E-induced genomic instability in primary human cells. We find that loss of p53 and Fbw7 synergistically unmasks cyclin E-induced instability. In normal cells, impaired cyclin E degradation produces genome instability, but this is rapidly mitigated by induction of p53 and p21. In contrast, p53 loss allows the high level of cyclin E kinase activity that results from Fbw7 loss to persist and continuously drive genome instability. Moreover, p21 plays a critical role in suppressing cyclin E when Fbw7 is disabled, and in the absence of p21, sustained cyclin E activity induces rapid cell death via apoptosis. These data directly demonstrate the cooperative roles of these Fbw7 and p53 pathways in restraining cyclin E activity and its associated genome instability.
and aberrant cyclin E activity causes genetic instability and tumorigenesis (Spruck et al., 1999; Minella et al., 2002; Loeb et al., 2005; Smith et al., 2006) . Many human cancers express high levels of cyclin E (Hwang and Clurman, 2005) , and this is thought to directly contribute to cell transformation and tumor aggressiveness.
Two pathways protect primary cells against excess cyclin E activity. The first is a p53-dependent response that suppresses cyclin E kinase activity through induction of the p21 Cdk inhibitor (see below; Minella et al., 2002; Loeb et al., 2005) . The second protective pathway is degradation of cyclin E by the SCF Fbw7hCdc4 ubiquitin ligase (Koepp et al., 2001; Moberg et al., 2001; Strohmaier et al., 2001; Welcker et al., 2003) . Fbw7 is an F-box protein that binds to a number of oncogenic proteins (cyclin E, Myc, Notch and Jun) after they are phosphorylated within conserved phosphodegron motifs, and Fbw7 is a tumor suppressor frequently deleted in human cancers (Oberg et al., 2001; Wu et al., 2001; Spruck et al., 2002; Ekholm-Reed et al., 2004; Nateri et al., 2004; Welcker et al., 2004; Yada et al., 2004; Wei et al., 2005) . Fbw7 loss also causes genetic instability due to aberrant cyclin E activity (Rajagopalan et al., 2004) .
Fbw7 binding is stimulated by cyclin E phosphorylation within two phosphodegrons: a C-terminal degron regulated by phosphorylations on threonine 380 and serine 384, and an N-terminal degron centered on threonine 62. Phosphorylation causes cyclin E to bind to the Fbw7 b-propeller and brings cyclin E into proximity with the SCF ubiquitination machinery (Orlicky et al., 2003) . Because T62, T380 and S384 are autophosphorylation sites, Fbw7 only targets cyclin E within catalytically active cyclin E-Cdk2 complexes (Clurman et al., 1996; Won and Reed, 1996; Welcker et al., 2003) . Thus, conditions that augment cyclin E activity, such as loss of p53 or p21, are countered by increased cyclin E degradation by the Fbw7 pathway (Welcker et al., 2003; Loeb et al., 2005) .
We previously found that increased cyclin E expression increases p53 abundance and p53 serine 15 phosphorylation (which activates p53; Minella et al., 2002; Loeb et al., 2005) . These effects on p53 were greater when cyclin E was rendered resistant to Fbw7 by mutation of threonine 380 to alanine (T380A). To examine the mechanism of p53 induction by cyclin E, we transduced U2OS cells and primary human fibroblasts with retroviral vectors encoding cyclin E-T380A. We first examined upstream kinases that promote p53 serine 15 phosphorylation by using antibodies that recognize the phosphorylated forms of Chk1 and Chk2 (these sites are targets of ataxia telangiectasia and Rad3-related protein (ATR) and ataxia telangiectasia mutated (ATM), respectively). We found that cyclin E increased the amount of serine 345-phosphorylated Chk1 but did not alter threonine 68-phosphorylated Chk2 (Figure 1a ). In combination with our previous findings that cyclin E-induced p53 serine 15 phosphorylation was blocked by pharmacologic ATR/ATM inhibitors, these data suggest that cyclin E deregulation causes p53 to be phosphorylated on serine 15 by a DNA damage-like signaling pathway (Minella et al., 2002) .
We next studied the mechanism of p53 accumulation by examining p53 synthesis and degradation. We first used pulse labeling with 35 S-methionine to examine the rate of p53 synthesis, and this was not altered by cyclin E expression (data not shown). In contrast, when cells were treated with cycloheximide to inhibit protein synthesis, cyclin E expression markedly prolonged p53 turnover in both Wi-38 and U2OS cells, indicating that p53 accumulation resulted primarily from decreased p53 turnover (Figure 1b) . Because serine 15 phosphorylation activates p53, but is not thought to regulate p53 degradation significantly (Dumaz and Meek, 1999) , cyclin E-induced p53 activation probably involves both serine 15 phosphorylation and prolonged p53 stability. sh-p53/control; Vector * Figure 1 p53 and p21 regulate cellular responses to cyclin E. (a) Primary human fibroblasts were transduced with control or cyclin E-expressing retrovirus. Viral supernatants, selection, cell lysis and immunoblotting were performed as described previously (Minella et al., 2002) . Antibodies: Chk1 and Chk2 (Cell Signaling, Danvers, MA, USA), cyclin E (HE12) and p53 (DO1) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and p21 (BD-Transduction Labs, Franklin Lakes, NJ, USA). (b) U2OS cells and primary Wi-38 human fibroblasts were transduced and selected as in (a). Cells were treated with 50 mg/ml cycloheximide for the indicated times, and lysates were quantitated and immunoblotted. U2OS lysates exhibit a non-specific, background band (NS) that serves as a loading control. (c) Wi-38 fibroblasts were transduced with vectors encoding either a control small hairpin RNA or one targeting p53 (sh-p53), selected, followed by control or cyclin E-expressing retroviruses. Histone H1 kinase activity was measured in anti-cyclin E immunoprecipitates as described by Clurman et al. (1996) . (d) Wi-38 cells used in (c) were plated on day 0 (4 Â 10 5 cells), counted on day 5, and re-plated and counted on day 10. Cells were counted manually in triplicate, and error bars indicate standard error. (e) Wi-38 cells were transduced with vectors encoding either control or p21 shRNAs (Noseda et al., 2004) , followed by control or cyclin E T380A. Top panels: right -sh-p21-expressing control cells exhibit full-length PARP (approximately 115 kDa, antibody from BD-Pharmingen, Franklin Lakes, NJ, USA) and a faint, faster migrating band. In contrast, cells expressing both sh-p21 and cyclin E-T380A exhibit only the cleaved PARP form (85 kDa) present in apoptotic cells. Left panel -partial PARP cleavage after UVC irradiation (positive control), but not when cyclin E-T380A alone is expressed. Bottom panels: cells were fixed in (1:3) acetic acid/methanol. Nuclei appeared normal in the sh-p21 cells expressing the control vector, but cyclin E-T380A expressing cells showed frequent nuclear fragmentation (indicated as arrowheads).
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Fbw7 and p53 pathways in retraining cyclin E activity AC Minella et al Because p53 induction increases p21 abundance and inactivates Cdk2, we tested the roles of p53 and p21 in regulating the proliferative responses to cyclin E expression. We transduced primary fibroblasts with vectors encoding a small hairpin RNA directed against p53 (sh-p53), or a control, and subsequently transduced the cells with vectors encoding wild-type (wt) cyclin E, cyclin E-T380A or control (Figure 1c) . The sh-p53 vector almost completely blocked p53 and p21 induction by cyclin E and allowed high levels of ectopic cyclin E Wi-38 cells were transduced with sh-p53-expressing retrovirus followed by the indicated cyclin E or control vectors. Cyclin E abundance (top panel) and cyclin E-associated histone H1 kinase activity (bottom panel) are shown. Lysates run in lane 2 were prepared from cells transduced with the cyclin E-expressing vector used in previous experiments that contains cyclin E 3 0 untranslated region sequence, whereas the vectors used in lanes 3 (wild-type cyclin E) and 4 (kd-cyclin E) were made from cells transduced with a vector that contains the cyclin E open-reading frame without untranslated sequence. (f) Micronuclei were counted in the cells (e) using the method described for (b). Error bars indicate standard deviations calculated from three independent experiments. FISH, fluorescence in situ hybridization.
Fbw7 and p53 pathways in retraining cyclin E activity AC Minella et al kinase activity (note the absence of cyclin E activity in cells expressing the control shRNA, despite high cyclin E expression; Figure 1c ). Similar to fibroblasts derived from constitutive cyclin E-T393A knock-in mice (the murine equivalent of human cyclin E-T380A; Loeb et al., 2005) , we found that acute cyclin E-T380A expression in primary human cells strongly inhibited cell proliferation and that this was rescued by p53 knockdown (Figure 1d ). To determine the role of p21 induction in this proliferative arrest, we used a previously characterized shRNA vector to knock down p21 expression and then expressed cyclin E-T380A (Noseda et al., 2004) . In contrast to p53 knockdown, cells expressing both sh-p21 and cyclin E-T380A died rapidly in culture. These findings were reminiscent of studies showing that p53 induces apoptosis rather than cell-cycle arrest in p21 null cells (Polyak et al., 1996) . Accordingly, we observed poly (ADP-ribose) polymerase (PARP) cleavage and severe chromatin fragmentation in cells expressing both sh-p21 and cyclin E-T380A, indicating that in the absence of p21 expression, deregulated cyclin E activity induces p53-dependent apoptosis ( Figure 1e ). Thus p21 plays at least two roles as primary cells respond to cyclin E deregulation: it inactivates cyclin E-associated kinase activity and it prevents cell death. We previously found that p53 loss was required for cyclin E to induce abnormal karyotypes in primary cells that were passaged after transduction with cyclin Eencoding vectors (Minella et al., 2002) . Moreover, when we examine genetic instability by scoring micronucleation rather than cytogenetic analysis of metaphase spreads, cyclin E causes instability within the first passage after transduction, and this occurs to a greater extent with cyclin E-T380A (Minella et al., 2005 ; Figure  2a and b, early). We also found numerous examples of abnormal mitoses with chromosomal fragmentation, suggesting that excess cyclin E was inducing mitotic catastrophe in a subset of the transduced cells (Figure 2a, top) . To reconcile the findings that p53 loss was required to observe cyclin E-induced instability in metaphase spreads but not when examining micronucleation immediately after transduction, we examined the impact of p53 early and later after cyclin E expression (Figure 2b ). We observed that cyclin E and cyclin E-T380A expression rapidly induced micronucleation and that this was increased by p53 loss. However, when we examined the amount of micronucleation in these same cell populations after two more passages, we found significantly reduced instability caused by cyclin E-T380A in the later passage cells. In contrast, when p53 was inactivated, the amount of cyclin E-T380A-induced instability in the later passage cells remained at similarly high levels as seen earlier. We also utilized two-color fluorescence in situ hybridization to score chromosome instability in the later passage cell populations and found that p53 loss and cyclin E-T380A expression cooperatively induced instability, and that this involved chromosome losses and gains (Figure 2d ). In fact, this assay underestimates the total number of chromosomal aberrations in these cells, because it only examines the two chromosomes detected by the alpha-satellite probes. These data indicate that deregulated cyclin E induces genetic instability, and that this is rapidly suppressed by p53, presumably via p21 induction and Cdk2 inhibition.
Recent work indicates that cyclin E performs a kinaseindependent function that involves loading minichromosome maintenance (MCM) proteins onto replication origins as quiescent cells enter the cell cycle (Geng et al., 2007) . Furthermore, cyclin E null cells resist transformation by dominant oncogenes, and this was surprisingly rescued by expression of a kinase-deficient (kd) cyclin E mutant. We thus utilized this kinasedeficient cyclin E mutant to examine the role of Cdk2 activity in cyclin E-induced genetic instability. We transduced sh-p53-expressing primary human fibroblasts with wild-type or kd-cyclin E and measured cyclin E abundance and kinase activity. As observed previously in other cell types (Geng et al., 2007) , kd-cyclin E had no detectable kinase activity in primary human fibroblasts, and it failed to induce micronucleation despite high-level Micronuclei (%) Figure 3 Fbw7 and p53 cooperatively restrain cyclin E kinase activity and genome instability. (a) Wi-38 cells were transduced with the indicated small hairpin-expressing constructs and following selection, lysates were prepared and immunoblotted to detect endogenous cyclin E and p21. Endogenous cyclin E kinase activity was measured as described and quantitated using a Typhoon phosphor-imager and ImageQuant software. (b) Micronuclei were counted for the indicated cell populations as described in Figure 2b and standard deviations calculated from three independent experiments. Using paired Student's t-test, P ¼ 0.001 was calculated for the difference in genome instability demonstrated in the sh-p53, sh-Fbw7-expressing cells, compared to the single knockdown and control cell populations.
expression (Figure 2e and f) . Thus, at least as measured by micronucleation, cyclin E-induced genetic instability requires cyclin E kinase activity. In sum, these data suggest that cyclin E deregulation rapidly induces genome instability in cultured primary cells without prerequisite loss of p53; however, the induction of p53/p21 in these cells inhibits ongoing genome damage by inactivating cyclin E-Cdk2. When p53 is lost, high cyclin E kinase activity is maintained, thus facilitating ongoing chromosomal instability. Furthermore, the loss of both Fbw7-mediated cyclin E degradation (caused by the T380A mutation) and p53 function was required for maximal cyclin E-induced instability, demonstrating the combined roles of these two pathways in countering cyclin E activity.
In the experiments above, cyclin E degradation was disabled by mutation of cyclin E itself, but in tumors, this pathway is inactivated by Fbw7 mutations. We thus determined if the instability caused by Fbw7 loss is also exacerbated by p53 loss. We transduced Wi-38 cells with a previously characterized vector expressing shRNA targeting Fbw7 (sh-Fbw7, Welcker et al., 2004) , or shFbw7 in combination with sh-p53, and examined the consequences on cyclin E activity and genetic instability. We found that acute Fbw7 depletion induced micronucleation, the first demonstration of Fbw7-induced genomic instability in primary human cells. Importantly, the inhibition of both p53 and Fbw7 cooperatively increased endogenous cyclin E-associated kinase activity (Figure 3a) . Because excess cyclin E activity triggers p53 and p21 induction, we examined p21 expression in these cells. We found that Fbw7-loss induced p21, and this was prevented when p53 was inhibited with shRNA. Thus, as with cyclin E overexpression, Fbw7 loss instigates a p53-dependent response that buffers cyclin E-associated kinase activity. Finally, we examined the consequences of combined p53 and Fbw7 loss on genetic instability and found that the combined loss of these two tumor suppressors cooperatively caused greater micronuclei formation than loss of either Fbw7 or p53 alone.
Other studies have suggested a somewhat different relationship between p53 and the genetic instability associated with deregulated cyclin E and Fbw7 loss. For example, Fbw7 heterozygosity was found to accelerate tumorigenesis in p53 heterozygous, but not in p53 null mice, suggesting that the cooperativity resulted primarily from loss of p53 driven by Fbw7-associated genome instability, and that once p53 was mutated, Fbw7 loss was no longer a cooperating event (Mao et al., 2004) . Similarly, p53 loss was suggested to be an early consequence of cyclin E transgene expression in a murine breast cancer model, again suggesting that p53 is the critical mutational target of cyclin E-induced instability (Smith et al., 2006) . However, while p53-loss is likely to be an important consequence of the genetic instability caused by Fbw7 loss or cyclin E gain, several lines of evidence indicate that p53 function also directly suppresses cyclin E-and Fbw7-associated genetic instability. First, ectopic cyclin E expression (or Fbw7 knockdown) in primary human cells directly increases p53 abundance and activity, and this inactivates cyclin E-Cdk2 through p21 induction (Minella et al., 2002) . Second, cyclin E-T393A knock-in mice (and cells derived from these mice) exhibit increased genetic instability and tumorigenesis that is dependent on p53 and/or p21 inactivation (Loeb et al., 2005) . Finally, our current work directly shows that an intact p53 pathway rapidly suppresses the instability associated with either cyclin E overexpression or Fbw7 loss. The cooperative activities of the p53 and Fbw7 pathways in suppressing cyclin E-induced genome instability highlight their roles as barriers against cyclin E-associated neoplasia.
